InspireMD Inc (STU:II2)

Q1 2025 InspireMD Inc Earnings Call Transcript

May 9, 2025 / 12:30 PM GMT

Release Date Price: €2.22 (-3.48%)

Transcript 8-K10-Q

Key Points

Positve

InspireMD Inc (NSPR) reported a 1.2% year-over-year growth in revenue, reaching $1.53 million for the first quarter of 2025.
The company has sold approximately 64,000 Seaguard stents to date, showcasing its expertise and strong market presence.
InspireMD Inc (NSPR) is optimistic about receiving FDA approval for Seaguard Prime in the third quarter of 2025, which is expected to drive significant demand.
The company has built a strong commercial and operational team in anticipation of the US launch, with 20 high-powered sales and marketing professionals already onboarded.
InspireMD Inc (NSPR) is advancing its clinical pipeline with strong enrollment in the Sea Guardians 2 pivotal study and plans for the Sea Guardians 3 IDE submission.

Negative

The company's gross profit for the first quarter of 2025 remained flat compared to the previous year, with a gross margin of only 19.1%.
Operating expenses increased by 52.5% to $11.75 million, primarily due to higher salaries and launch preparations.
Net loss for the first quarter of 2025 was $11.17 million, a significant increase from the previous year's net loss of $732,000.
Cash and cash equivalents decreased substantially to $2.69 million as of March 30, 2025, from $34.64 million at the end of 2024.
The timeline for FDA approval of Seaguard Prime has been slightly pushed to Q3 2025 due to delays in the facility site audit and subsequent feedback process.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NSPR.OQ - InspireMD Inc
Q1 2025 InspireMD Inc Earnings Call
May 09, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please stand by. Your program is about to begin.

If you need audio assistance during today's program, please press 0.

Good morning and welcome to Inspire MD's first quarter 2025 earnings conference call.

Currently all participants are in a listen-only mode.

We will be facilitating a question answer session towards the end of today's call.

As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Web Campbell from Gil Martin Group for introductory disclosures.

--------------------------------------------------------------------------------
Unidentified_2 [2]
------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.